# Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s

> **NCT03457597** · PHASE1 · COMPLETED · sponsor: **Corcept Therapeutics** · enrollment: 27 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Midazolam hydrochloride
- **DRUG:** Metoprolol tartrate
- **DRUG:** Pioglitazone hydrochloride
- **DRUG:** Tolbutamide
- **DRUG:** Omeprazole
- **DRUG:** Relacorilant

## Key facts

- **NCT ID:** NCT03457597
- **Lead sponsor:** Corcept Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-06
- **Primary completion:** 2018-04-15
- **Final completion:** 2018-04-28
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2018-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03457597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03457597, "Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03457597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*